Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $855000.0.

  • Harvard Bioscience's Amortization - Intangibles fell 3590.7% to $855000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 1766.02%. This contributed to the annual value of $5.3 million for FY2024, which is 488.69% down from last year.
  • Latest data reveals that Harvard Bioscience reported Amortization - Intangibles of $855000.0 as of Q3 2025, which was down 3590.7% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Amortization - Intangibles peaked at $1.6 million during Q4 2022, and registered a low of $855000.0 during Q3 2025.
  • For the 5-year period, Harvard Bioscience's Amortization - Intangibles averaged around $1.4 million, with its median value being $1.4 million (2023).
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first surged by 1263.89% in 2022, then tumbled by 3590.7% in 2025.
  • Over the past 5 years, Harvard Bioscience's Amortization - Intangibles (Quarter) stood at $1.4 million in 2021, then rose by 12.64% to $1.6 million in 2022, then decreased by 14.49% to $1.4 million in 2023, then dropped by 9.37% to $1.3 million in 2024, then plummeted by 31.98% to $855000.0 in 2025.
  • Its last three reported values are $855000.0 in Q3 2025, $1.2 million for Q2 2025, and $1.2 million during Q1 2025.